Moderna, Inc. (MRNA)
Moderna Inc Investors Can Participate In Fraud Investigations With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pomerantz Law Firm Announces the Filing of a Class Action Against Moderna, Inc. and Certain Officers – MRNA
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv- 12058, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Moderna securities between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Moderna Inc Investors Eligible To Join Fraud Investigations With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Moderna Inc Investors Can Join Fraud Investigations With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Moderna Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna stock, which lost 27% of its value over two days, tumbled again Monday on a rare downgrade amid uncertainty for its vaccines.
Cathie Wood Bought This Stock After Its 27% Drop. Should You?
Famous investor Cathie Wood is known for scooping up great stocks when they're down. She focuses on the long-term picture rather than the company's near-term, temporary challenges.
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
On Thursday, Moderna Inc MRNA lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines.
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
COVID-19 vaccine maker Moderna, Inc. MRNA fell over 21% on Thursday after the company reduced its revenue guidance for the year, citing a highly competitive respiratory vaccine market in the U.S. and weak COVID-19 vaccine sales in Europe.
Moderna Q2: Focus On The Light At The End Of The Tunnel
Moderna investors suffered a 20% hammering yesterday as the market reacted to a downward guidance revision. However, Covid isn't expected to disappear. The market reset should help prime MRNA for a second-half recovery. Moderna's RSV vaccine could also help drive a re-rating in the second half.
Cathie Wood's Ark ETFs buy a bunch of Moderna stock after record selloff
High-profile investor Cathie Wood saw the record selloff in Moderna Inc.'s stock as an opportunity to bulk up her bets on the biotechnology company.
S&P 500 Gains and Losses Today: Moderna Drops as Soft Vaccine Demand Prompts Guidance Cut
Major U.S. equities indexes moved lower on the first day of August as a pair of reports elevated concerns about the trajectory of the U.S. economy.
